<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19440" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chlorpromazine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mann</surname>
            <given-names>Sukhmanjeet Kaur</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marwaha</surname>
            <given-names>Raman</given-names>
          </name>
          <aff>Case Western Reserve Un/MetroHealth MC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sukhmanjeet Kaur Mann declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Raman Marwaha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19440.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Chlorpromazine is a medication used to manage and treat schizophrenia, bipolar disorder, and acute psychosis. It is a member of the typical antipsychotics or neuroleptic medication category, also known as first-generation antipsychotics. This activity illustrates the use of chlorpromazine in relieving nausea and vomiting. It outlines the indications, actions, adverse effects, contraindications, and other key elements of chlorpromazine therapy in the clinical settings used by healthcare professionals in managing patients with schizophrenia, bipolar disorders, and related psychosis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of chlorpromazine.</p></list-item><list-item><p>Describe the potential adverse effects of chlorpromazine.</p></list-item><list-item><p>Outline the importance of monitoring patients on chlorpromazine and describe the symptoms of the toxicity.</p></list-item><list-item><p>Explain the importance of improving care coordination and communication among interprofessional team members to improve the outcomes of patients after initiating treatment with chlorpromazine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19440&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19440">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19440.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Chlorpromazine is a typical antipsychotic medication primarily used to treat&#x000a0;psychiatric disorders such as schizophrenia, but it has other indications.<xref ref-type="bibr" rid="article-19440.r1">[1]</xref> Chlorpromazine's indications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Schizophrenia (primarily the positive symptoms)</p>
          </list-item>
          <list-item>
            <p>Bipolar I acute manic type of manic-depressive illness</p>
          </list-item>
          <list-item>
            <p>Acute agitation marked by explosive hyperexcitable behavior out of proportion to the initial provocation</p>
          </list-item>
          <list-item>
            <p>To control nausea and vomiting, including intraoperative nausea and vomiting</p>
          </list-item>
          <list-item>
            <p>Persistent singultus (chronic hiccups)</p>
          </list-item>
          <list-item>
            <p>Relief of apprehension before surgery</p>
          </list-item>
          <list-item>
            <p>Adjunct treatment of tetanus</p>
          </list-item>
          <list-item>
            <p>Acute intermittent porphyria</p>
          </list-item>
          <list-item>
            <p>Adjunct treatment of serotonin syndrome (off-label)</p>
          </list-item>
          <list-item>
            <p>Migraine-associated relief of nausea and vomiting (off-label)</p>
          </list-item>
        </list>
        <p>The efficacy of chlorpromazine in bipolar disorder was mainly established to control the manic episode of bipolar illness, such as excessive energy, decreased need for sleep,&#x000a0;increased excitability and impulsivity, and grandiose ideations. Chlorpromazine is the Food and Drug Administration (FDA)-approved treatment for persistent singultus, a medical problem where hiccupping lasts more than 48 hours. Regarding acute psychosis, studies have shown that chlorpromazine has been effective as a short-term treatment in controlling combativeness and aggressive behavior in children.<xref ref-type="bibr" rid="article-19440.r2">[2]</xref><xref ref-type="bibr" rid="article-19440.r3">[3]</xref></p>
      </sec>
      <sec id="article-19440.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Chlorpromazine&#x000a0;is a member of the typical antipsychotic or neuroleptic drug class, also known as first-generation antipsychotics (FGAs). Its precise mechanism of action is unknown, but it is believed to produce its antipsychotic effect by the post-synaptic blockade at the D2 receptors in the mesolimbic pathway. However, blocking D2 receptors in the nigrostriatal pathway is responsible for its extrapyramidal side effects.<xref ref-type="bibr" rid="article-19440.r4">[4]</xref>&#x000a0;</p>
        <p>The antiemetic effect of chlorpromazine stems from the combined blockade of histamine H1, dopamine D2, and muscarinic M1 receptors in the vomiting center.</p>
        <p>Chlorpromazine is extensively metabolized by the liver (CYP450 enzymes 1A2 and 2D6; it is a CYP3A4 substrate). It also undergoes metabolism in the kidney and GI tract. It is excreted in the urine, bile, and feces. It has a half-life of between 23 and 37 hours for the parent drug, and its active metabolite has a half-life of 10 to 40 hours.</p>
      </sec>
      <sec id="article-19440.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The medication is available&#x000a0;as tablets (10 mg, 25 mg, 50 mg, 100 mg, and 200 mg) for oral intake and can also be administered as intramuscular and intravenous injections. Dosage decisions are on a patient-by-patient basis.<xref ref-type="bibr" rid="article-19440.r5">[5]</xref></p>
        <p>For the treatment of schizophrenia, the patient is initially started on 25&#x000a0;to 75 mg/day orally twice a day and maintained at 200 mg/day. However, the maximum dose per oral&#x000a0;is 800 mg/day. If given by intramuscular or intravenous route, it is initially started at 25 mg, followed as needed by 25&#x000a0;to 50 mg after 1&#x000a0;to 4 hours. The usual dose can be 300-800 mg/day.</p>
        <p>To treat nausea and vomiting, chlorpromazine dose can range from 10&#x000a0;to 25 mg orally every&#x000a0;4&#x000a0;to 6 hours as needed. If used as an intramuscular or intravenous injection, the dose can range from 25&#x000a0;to 50 mg every 4&#x000a0;to 6 hours as needed.</p>
        <p>Persistent singultus can be treated by giving 25&#x000a0;to 50 mg of chlorpromazine&#x000a0;orally every 6&#x000a0;to 8 hours. If hiccups persist after 2 to 3 days of oral treatment, chlorpromazine is given as an intramuscular or intravenous dose.</p>
        <p>To control preoperative apprehension, the dose for chlorpromazine can range from 25&#x000a0;to 50 mg orally and 12.5 to 25 mg intramuscularly given 2&#x000a0;to 3 hours before surgery.</p>
        <p>There is no need for renal dose adjustments, and for patients on dialysis, no supplement is necessary. For patients with hepatic impairment, caution is advised.<xref ref-type="bibr" rid="article-19440.r6">[6]</xref></p>
      </sec>
      <sec id="article-19440.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Chlorpromazine is a low-potency antipsychotic that mainly causes non-neurologic side effects. It is highly lipid-soluble and stored in body fats, thus very slow to be removed from the body. Being a low-potency typical antipsychotic, it primarily causes dry mouth, dizziness, urine retention, blurred vision, and constipation by blocking the muscarinic receptors. There is a risk of angle-closure glaucoma in older patients. It also causes sedation due to the blockade of histamine H1 receptors.</p>
        <p>Antagonism at the D2 receptors in the tuberoinfundibular pathway is believed to be responsible for the increase in the prolactin level. This hyperprolactinemia can cause several endocrinal side effects, such as decreased libido in both genders. In males, increased prolactin may cause gynecomastia, galactorrhea, and erectile dysfunction. Rarely, it may cause priapism. In females, increased prolactin levels may result in irregular menstruation, oligomenorrhea, amenorrhea, and galactorrhea.&#x000a0;</p>
        <p>When administered as intramuscular or intravenous injections, it may cause hypotension and headache. Prolonged use of chlorpromazine may cause corneal deposits and lens opacity. It may prolong the QT interval. Studies have shown that chlorpromazine may also result in cholestatic jaundice by impairing the bile flow. The drug-induced hepatotoxicity results from inflammation and injury to the liver, which may significantly increase the alanine aminotransferase level (ALT). It can be prevented by regular monitoring with liver function tests, and in case of the early detection of liver injury, the drug should be stopped, and symptomatic management should start.<xref ref-type="bibr" rid="article-19440.r7">[7]</xref><xref ref-type="bibr" rid="article-19440.r8">[8]</xref></p>
        <p>Despite being a low-potency drug, chlorpromazine can still cause extrapyramidal side effects (EPS) such as acute dystonia, akathisia, parkinsonism, and tardive dyskinesia (TD). The evolution of EPS side effects can occur from hours to days. Acute dystonia refers to muscle stiffness or spasms of the head, neck, and eye muscles that can start hours after starting the medication. Akathisia includes restlessness and fast pacing. Parkinsonism includes bradykinesia, "cogwheel" rigidity, and shuffling gait. TD results from prolonged exposure to antipsychotic drugs and includes involuntary, repetitive, abnormal movements of the face and extremities.&#x000a0;Patients are at risk of developing neuroleptic malignant syndrome (NMS). In this life-threatening manifestation, the patient presents with "lead-pipe" muscle rigidity, autonomous instability, hyperpyrexia of more than 40 degrees Celsius, altered mental status, leukocytosis, and elevated serum creatinine kinase.<xref ref-type="bibr" rid="article-19440.r9">[9]</xref><xref ref-type="bibr" rid="article-19440.r10">[10]</xref></p>
      </sec>
      <sec id="article-19440.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Chlorpromazine should not be given if there is a known hypersensitivity or allergy to phenothiazines. The drug should be used cautiously in patients on antihypertensive medications due to the risk of developing severe hypotension. It should not be administered concurrently with drugs that depress the central nervous system or patients with poorly controlled seizure disorder. The drug does not have approval for the treatment of dementia-related psychosis. Chlorpromazine's D2 receptor blockade action may affect the therapeutic efficacy of medications with dopamine agonist action, such as levodopa or cabergoline. Selective-serotonin reuptake inhibitors such as citalopram and escitalopram are contraindicated to use along with chlorpromazine. Studies have shown that chlorpromazine qualifies as a potential drug for use during breastfeeding, but under medical supervision,&#x000a0;when the benefits outweigh the risks.<xref ref-type="bibr" rid="article-19440.r11">[11]</xref></p>
        <p>Chlorpromazine occasionally may be used in low doses during pregnancy, although clinicians should weigh the risk vs. benefit of therapy during pregnancy, particularly in the third trimester.<xref ref-type="bibr" rid="article-19440.r12">[12]</xref>&#x000a0;Likewise, breastfeeding mothers may use chlorpromazine short-term, but it comes down to risk vs. benefit analysis for the prescribing clinician.<xref ref-type="bibr" rid="article-19440.r13">[13]</xref></p>
      </sec>
      <sec id="article-19440.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The hepatic P450 enzyme CYP2D6 metabolizes the drug, and its half-life is approximately 30 hours. It gets excreted from the body via urine and bile. Studies have shown a correlation between chlorpromazine's therapeutic level and improving psychiatric symptoms. Researchers have noted that the patients receiving chronic treatment with chlorpromazine have lower plasma levels as compared to the patients acutely treated with an oral dose of chlorpromazine. Also, the concomitant use of anticholinergics can affect the plasma concentration of chlorpromazine. However, the plasma level and the response threshold for clinical improvement of symptoms and toxicity using chlorpromazine differ both for children and adults.<xref ref-type="bibr" rid="article-19440.r14">[14]</xref></p>
      </sec>
      <sec id="article-19440.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Patients who are allergic to phenothiazines can develop hypersensitive anaphylactic reactions with chlorpromazine. Such patients can be treated by discontinuing the drug and administering steroids or antihistaminic drugs. Chlorpromazine use also requires caution in patients with cerebrovascular and cardiovascular diseases. Patients should start on a low dose of chlorpromazine as an initial dosage, and the increase in subsequent dosing should be gradual. However, treatment should be discontinued if the patient develops agranulocytosis.<xref ref-type="bibr" rid="article-19440.r8">[8]</xref></p>
        <p>In the event of an overdose, ensure adequate ventilation. No specific antidote is available, and treatment primarily addresses&#x000a0;symptoms&#x000a0;with regular cardiac and respiratory monitoring. Gastric lavage may be attempted if the patient presents to the emergency department within 4&#x000a0;to 6 hours. Activated charcoal is also an option. ECGs are necessary to assess for arrhythmias or QT-interval prolongation. NMS should be treated supportively with cooling and by giving dantrolene sodium.&#x000a0;Treatment for TD can be done by discontinuing chlorpromazine and starting a second-generation antipsychotic along with valbenazine or deutetrabenazine.&#x000a0;</p>
      </sec>
      <sec id="article-19440.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Chlorpromazine is a low-potency antipsychotic drug that is usually started by a psychiatrist. However, the patient's follow-up on the drug can involve many healthcare professionals on the interprofessional team, including primary care providers, mid-level practitioners (NPs and PAs), psychologists, pharmacists, nurses, or emergency department personnel. Psychiatric nurses monitor patients, provide education, and inform the prescriber of any concerns, such as adverse events or therapeutic ineffectiveness. Pharmacists review the dosage, perform drug interaction checks, and educate patients about the importance of compliance and side effects. Adequate communication is necessary among the providers for effective patient care and to limit medical errors. Patients should be assessed for movement disorder and blood work; ECGs should be obtained&#x000a0;at regular visits.</p>
        <p>If the side effects are present at any level, effective communication should occur, and referrals should be made to help the patients maintain an adequate quality of life. Patients should understand to limit the consumption of alcohol and consume a healthy meal while on the drug. Interprofessional teamwork is a necessary component of successful therapy with chlorpromazine. [Level 5]</p>
      </sec>
      <sec id="article-19440.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19440&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19440">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19440/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19440">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19440.s11">
        <title>References</title>
        <ref id="article-19440.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jufe</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>[Evolution of antipsychotics and their use in the treatment of schizophrenia. What's up, doc?].</article-title>
            <source>Vertex</source>
            <year>2011</year>
            <season>Nov-Dec</season>
            <volume>22</volume>
            <issue>100</issue>
            <fpage>423</fpage>
            <page-range>423-9</page-range>
            <pub-id pub-id-type="pmid">22799143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valdovinos</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Frazee</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Hailozian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haro</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Herring</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>A Nonopioid, Nonbenzodiazepine Treatment Approach for Intractable Nausea and Vomiting in the Emergency Department.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-332</page-range>
            <pub-id pub-id-type="pmid">31567626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kohse</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Hollmann</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Bardenheuer</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Chronic Hiccups: An Underestimated Problem.</article-title>
            <source>Anesth Analg</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>125</volume>
            <issue>4</issue>
            <fpage>1169</fpage>
            <page-range>1169-1183</page-range>
            <pub-id pub-id-type="pmid">28759492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seeman</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>History of the dopamine hypothesis of antipsychotic action.</article-title>
            <source>World J Psychiatry</source>
            <year>2021</year>
            <month>Jul</month>
            <day>19</day>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>355</fpage>
            <page-range>355-364</page-range>
            <pub-id pub-id-type="pmid">34327128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barra</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sin</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Safety and Effectiveness of Intravenous Chlorpromazine for Agitation in Critically Ill Patients.</article-title>
            <source>J Intensive Care Med</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>1118</fpage>
            <page-range>1118-1122</page-range>
            <pub-id pub-id-type="pmid">30558470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medina-Caliz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gonzalez-Jimenez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cabello</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Mayoral-Cleries</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lucena</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.</article-title>
            <source>Drug Saf</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>10</issue>
            <fpage>925</fpage>
            <page-range>925-43</page-range>
            <pub-id pub-id-type="pmid">27449495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velayudham</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced cholestasis.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2003</year>
            <month>May</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>287</fpage>
            <page-range>287-304</page-range>
            <pub-id pub-id-type="pmid">12904107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martucci</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kozlowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gamal</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Brzeszczy&#x00144;ski</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Treskes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Samuel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bagnaninchi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brzeszczynska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Plevris</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Chlorpromazine toxicity is associated with disruption of cell membrane integrity and initiation of a pro-inflammatory response in the HepaRG hepatic cell line.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>111</volume>
            <fpage>1408</fpage>
            <page-range>1408-1416</page-range>
            <pub-id pub-id-type="pmid">30841456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patterson-Lomba</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ayyagari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.</article-title>
            <source>BMC Neurol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>20</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>174</fpage>
            <pub-id pub-id-type="pmid">31325958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.</article-title>
            <source>J Med Toxicol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-31</page-range>
            <pub-id pub-id-type="pmid">19191213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klinger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fusar-Poli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Merlob</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic drugs and breastfeeding.</article-title>
            <source>Pediatr Endocrinol Rev</source>
            <year>2013</year>
            <season>Mar-Apr</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>308</fpage>
            <page-range>308-17</page-range>
            <pub-id pub-id-type="pmid">23724438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Einarson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boskovic</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Use and safety of antipsychotic drugs during pregnancy.</article-title>
            <source>J Psychiatr Pract</source>
            <year>2009</year>
            <month>May</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-92</page-range>
            <pub-id pub-id-type="pmid">19461391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Chlorpromazine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30000600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19440.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivera-Calimlim</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Problems in therapeutic blood monitoring of chlorpromazine.</article-title>
            <source>Ther Drug Monit</source>
            <year>1982</year>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-9</page-range>
            <pub-id pub-id-type="pmid">7041337</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
